Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NUWE
Upturn stock ratingUpturn stock rating

Nuwellis Inc (NUWE)

Upturn stock ratingUpturn stock rating
$0.24
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: NUWE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $11

1 Year Target Price $11

Analysts Price Target For last 52 week
$11Target price
Low$0.21
Current$0.24
high$5.84

Analysis of Past Performance

Type Stock
Historic Profit -71.84%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.65M USD
Price to earnings Ratio 0.02
1Y Target Price 11
Price to earnings Ratio 0.02
1Y Target Price 11
Volume (30-day avg) 1
Beta 0.46
52 Weeks Range 0.21 - 5.84
Updated Date 06/30/2025
52 Weeks Range 0.21 - 5.84
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 15.01

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -112.09%
Operating Margin (TTM) -160.71%

Management Effectiveness

Return on Assets (TTM) -83.67%
Return on Equity (TTM) -440.77%

Valuation

Trailing PE 0.02
Forward PE -
Enterprise Value -1054550
Price to Sales(TTM) 0.19
Enterprise Value -1054550
Price to Sales(TTM) 0.19
Enterprise Value to Revenue 0.22
Enterprise Value to EBITDA -0.34
Shares Outstanding 4373970
Shares Floating 3367168
Shares Outstanding 4373970
Shares Floating 3367168
Percent Insiders 23.2
Percent Institutions 7.89

Analyst Ratings

Rating 1
Target Price 11
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Nuwellis Inc

stock logo

Company Overview

overview logo History and Background

Nuwellis Inc., formerly CHF Solutions, Inc., focuses on developing, manufacturing, and commercializing medical devices for ultrafiltration therapy. Founded to address fluid overload in patients with heart failure and related conditions, the company aims to provide precise and controlled fluid removal.

business area logo Core Business Areas

  • Aquadex FlexFlow System: This is their primary product, designed for controlled fluid removal (ultrafiltration) in patients suffering from fluid overload, a common complication of heart failure, kidney disease, and other conditions.

leadership logo Leadership and Structure

Nuwellis's leadership team consists of executives with experience in medical device development, sales, and marketing. The organizational structure includes departments for research and development, manufacturing, commercial operations, and administration.

Top Products and Market Share

overview logo Key Offerings

  • Aquadex FlexFlow System: The Aquadex FlexFlow system is a standalone device and related single-use disposables for ultrafiltration. It is used in both adult and pediatric patients. Market share data is not readily available. Competitors include companies offering diuretics and other fluid management therapies. There is no single device competitor. Rather, Nuwellis is competing to change how fluids are removed, from medication to a mechanical approach.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is dynamic, with ongoing technological advancements and increasing demand for innovative solutions in fluid management and critical care. The market is driven by the rising prevalence of heart failure, kidney disease, and related conditions that cause fluid overload.

Positioning

Nuwellis is positioned as a provider of specialized ultrafiltration therapy for patients with fluid overload. Its competitive advantage lies in its Aquadex system, which offers precise and controlled fluid removal compared to traditional diuretics.

Total Addressable Market (TAM)

The TAM for fluid overload management is substantial, encompassing a significant portion of heart failure and kidney disease patients. Nuwellis is positioned to capture a portion of this market with its Aquadex system, focusing on patients who do not respond adequately to diuretics.

Upturn SWOT Analysis

Strengths

  • Specialized ultrafiltration technology
  • Targeted solution for fluid overload
  • Potential for improved patient outcomes compared to diuretics
  • FDA cleared

Weaknesses

  • Limited product portfolio
  • Relatively small market presence compared to larger medical device companies
  • Reliance on adoption of ultrafiltration therapy by physicians
  • Ongoing need for clinical data to support efficacy

Opportunities

  • Expansion into new indications beyond heart failure
  • Partnerships with hospitals and healthcare systems
  • International market expansion
  • Development of next-generation ultrafiltration devices
  • Increased awareness of ultrafiltration benefits

Threats

  • Competition from established pharmaceutical companies offering diuretics
  • Slow adoption of new technologies by healthcare providers
  • Regulatory hurdles and reimbursement challenges
  • Potential for adverse events associated with ultrafiltration

Competitors and Market Share

competitor logo Key Competitors

  • No direct competitor, current competitive landscape revolves around diuretics provided by big pharma.

Competitive Landscape

Nuwellisu2019s competitive advantage lies in its Aquadex system, which offers precise and controlled fluid removal compared to traditional diuretics. However, it faces the challenge of convincing physicians to adopt a new approach to fluid management.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trends can only be obtained from Nuwellis Inc.'s investor relations page.

Future Projections: Future growth projections are reliant upon analyst estimates which are subject to change.

Recent Initiatives: Recent strategic initiatives may include product development, clinical trials, and commercial partnerships. Please refer to Nuwellis Inc.'s press releases and investor relations materials for more details.

Summary

Nuwellis Inc. specializes in ultrafiltration therapy, primarily with its Aquadex system. Its competitive edge is precise fluid removal compared to diuretics, but adoption by healthcare providers poses a challenge. The company operates in a growing market driven by heart failure and kidney disease prevalence. However, small company size relative to big pharma in current diuretic market and reliance on a single product line present risks, balanced by opportunities for expansion and partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Nuwellis Inc. investor relations page
  • Industry reports
  • Analyst estimates

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nuwellis Inc

Exchange NASDAQ
Headquaters Eden Prairie, MN, United States
IPO Launch date 2012-02-16
Interim President, Interim CEO & Chairman of the Board Mr. John L. Erb
Sector Healthcare
Industry Medical Devices
Full time employees 38
Full time employees 38

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovak Republic, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.